Abstract
Purpose of review:
The article provides an overview of efforts to identify and validate biomarkers in acute respiratory distress syndrome (ARDS) and a discussion of the challenges confronting researchers in this area.
Recent findings:
Although various putative biomarkers have been investigated in ARDS, the data have been largely disappointing and the 'troponin' of ARDS remains elusive. Establishing a relationship between measurable biological processes and clinical outcomes is vital to advancing clinical trials in ARDS and expanding our arsenal of treatments for this complex syndrome.
Summary:
This article summarizes the current status of ARDS biomarker research and provides a framework for future investigation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Biomarkers / blood
-
Female
-
Humans
-
Intercellular Adhesion Molecule-1 / blood
-
Interleukin-6 / blood
-
Interleukin-8 / blood
-
Male
-
Mucin-1 / blood
-
Plasminogen Activator Inhibitor 1 / blood
-
Receptor for Advanced Glycation End Products / blood
-
Research
-
Respiration, Artificial / adverse effects*
-
Respiratory Distress Syndrome / blood
-
Respiratory Distress Syndrome / therapy*
-
Tumor Necrosis Factor-alpha / blood
-
Vascular Endothelial Growth Factor A / blood
-
Ventilator-Induced Lung Injury / blood
-
Ventilator-Induced Lung Injury / therapy*
-
Vesicular Transport Proteins / blood
-
von Willebrand Factor / metabolism
Substances
-
Biomarkers
-
Interleukin-6
-
Interleukin-8
-
MUC1 protein, human
-
Mucin-1
-
Plasminogen Activator Inhibitor 1
-
Receptor for Advanced Glycation End Products
-
SERPINE1 protein, human
-
Tumor Necrosis Factor-alpha
-
VEGFA protein, human
-
VPS51 protein, human
-
Vascular Endothelial Growth Factor A
-
Vesicular Transport Proteins
-
von Willebrand Factor
-
Intercellular Adhesion Molecule-1